KR102466192B1 - 간세포성 암종의 치료를 위한 조합 요법 - Google Patents

간세포성 암종의 치료를 위한 조합 요법 Download PDF

Info

Publication number
KR102466192B1
KR102466192B1 KR1020197008327A KR20197008327A KR102466192B1 KR 102466192 B1 KR102466192 B1 KR 102466192B1 KR 1020197008327 A KR1020197008327 A KR 1020197008327A KR 20197008327 A KR20197008327 A KR 20197008327A KR 102466192 B1 KR102466192 B1 KR 102466192B1
Authority
KR
South Korea
Prior art keywords
delete delete
pharmaceutically acceptable
amino
inhibitor
cdk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197008327A
Other languages
English (en)
Korean (ko)
Other versions
KR20190040996A (ko
Inventor
아난드 셀바라즈
피터 스미스
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20190040996A publication Critical patent/KR20190040996A/ko
Application granted granted Critical
Publication of KR102466192B1 publication Critical patent/KR102466192B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197008327A 2016-08-23 2017-08-23 간세포성 암종의 치료를 위한 조합 요법 Active KR102466192B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378455P 2016-08-23 2016-08-23
US62/378,455 2016-08-23
PCT/US2017/048183 WO2018039324A1 (en) 2016-08-23 2017-08-23 Combination therapies for the treatment of hepatocellular carcinoma

Publications (2)

Publication Number Publication Date
KR20190040996A KR20190040996A (ko) 2019-04-19
KR102466192B1 true KR102466192B1 (ko) 2022-11-14

Family

ID=59772765

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197008327A Active KR102466192B1 (ko) 2016-08-23 2017-08-23 간세포성 암종의 치료를 위한 조합 요법

Country Status (14)

Country Link
US (1) US20190175598A1 (https=)
EP (1) EP3503923B1 (https=)
JP (1) JP7190425B2 (https=)
KR (1) KR102466192B1 (https=)
CN (1) CN109803684B (https=)
AU (1) AU2017315357B2 (https=)
BR (1) BR112019003722A2 (https=)
CA (1) CA3034875C (https=)
ES (1) ES2966469T3 (https=)
IL (1) IL264950B2 (https=)
MX (1) MX2019002115A (https=)
RU (1) RU2769251C2 (https=)
SG (1) SG11201901472TA (https=)
WO (1) WO2018039324A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3738084A4 (en) 2018-01-08 2021-11-17 G1 Therapeutics, Inc. SUPERIOR G1T38 DOSING SCHEMES
EP4309656A3 (en) 2018-05-14 2024-02-28 Pfizer Inc. Oral solution formulation
TW202128174A (zh) * 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
JP2023533903A (ja) * 2020-05-15 2023-08-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｆｇｆｒ４阻害剤の経口製剤によるがんの治療方法
JP2025520303A (ja) 2022-05-30 2025-07-03 石▲薬▼集▲團▼中奇制▲薬▼技▲術▼（石家庄）有限公司 癌治療用の医薬組み合わせ物および医薬組成物
TW202523318A (zh) * 2023-11-30 2025-06-16 大陸商石藥集團中奇製藥技術（石家莊）有限公司 聯合治療腫瘤的藥物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
DE19959546A1 (de) 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen
IL150643A0 (en) 2000-01-18 2003-02-12 Aventis Pharma Inc Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 [4r-(3s-hydroxy-1-methyl) piperidinyl]-4h-1-benzopyran-4-one
HUP0204126A3 (en) 2000-01-18 2006-02-28 Aventis Pharma Inc Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one, process for their preparation and pharmaceutical compositions containing them
US20050004007A1 (en) 2000-09-12 2005-01-06 Steven Grant Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents
MXPA04005939A (es) 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
CA2532965C (en) 2003-07-22 2013-05-14 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
WO2008007113A2 (en) 2006-07-14 2008-01-17 Astex Therapeutics Limited Pharmaceutical combinations
CN101146532B (zh) 2005-01-21 2012-05-09 阿斯泰克斯治疗有限公司 药物化合物
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
EP1845975A1 (en) 2005-01-21 2007-10-24 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
JP2008255008A (ja) 2005-07-19 2008-10-23 Tokyo Medical & Dental Univ 滑膜細胞増殖抑制剤
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
EP2043635A2 (en) 2006-06-29 2009-04-08 Astex Therapeutics Limited Pharmaceutical combinations
EP2046330A2 (en) 2006-07-14 2009-04-15 Astex Therapeutics Limited Pharmaceutical combinations
WO2008009954A1 (en) 2006-07-21 2008-01-24 Astex Therapeutics Limited Medical use of cyclin dependent kinases inhibitors
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
US7902147B2 (en) 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
ES2554513T3 (es) * 2008-05-23 2015-12-21 Novartis Ag Derivados de quinolinas y quinoxalinas como inhibidores de la proteína tirosina quinasa
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
EP2558092B1 (en) 2010-04-13 2018-06-27 Novartis AG Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
MX338327B (es) 2010-10-25 2016-04-12 G1 Therapeutics Inc Inhibidores de cdk.
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
EP2937349B1 (en) * 2011-03-23 2016-12-28 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
KR20140040769A (ko) * 2011-07-01 2014-04-03 노파르티스 아게 조합 요법
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
US9867825B2 (en) 2012-12-20 2018-01-16 Novartis Ag Pharmaceutical combination comprising binimetinib
PL2945628T3 (pl) * 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
ME03557B (me) 2013-03-15 2020-07-20 G1 Therapeutics Inc Privremena zaštiтa normalnih ćelija током hemoterapije
CN105828822B (zh) * 2013-08-14 2019-10-18 诺华股份有限公司 用于治疗癌症的组合疗法
PH12016500676B1 (en) * 2013-10-18 2022-07-20 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
WO2016025650A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN104529904B (zh) 2015-01-09 2016-08-31 苏州明锐医药科技有限公司 玻玛西尼的制备方法
WO2016126889A1 (en) 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
KR102548229B1 (ko) * 2015-04-14 2023-06-27 에자이 알앤드디 매니지먼트 가부시키가이샤 결정질 fgfr4 억제제 화합물 및 그의 용도

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
공개특허공보 제10-2016-0072113호 (2016.06.22.)*

Also Published As

Publication number Publication date
IL264950B2 (en) 2024-01-01
EP3503923A1 (en) 2019-07-03
KR20190040996A (ko) 2019-04-19
MX2019002115A (es) 2019-07-08
US20190175598A1 (en) 2019-06-13
RU2769251C2 (ru) 2022-03-29
AU2017315357B2 (en) 2022-12-01
JP2019528302A (ja) 2019-10-10
AU2017315357A1 (en) 2019-02-28
CN109803684A (zh) 2019-05-24
RU2019108259A3 (https=) 2020-11-24
CA3034875A1 (en) 2018-03-01
ES2966469T3 (es) 2024-04-22
BR112019003722A2 (pt) 2019-05-28
CA3034875C (en) 2024-05-28
CN109803684B (zh) 2022-08-23
EP3503923B1 (en) 2023-10-04
IL264950B1 (en) 2023-09-01
RU2019108259A (ru) 2020-09-25
WO2018039324A1 (en) 2018-03-01
JP7190425B2 (ja) 2022-12-15
SG11201901472TA (en) 2019-03-28
IL264950A (en) 2019-05-30

Similar Documents

Publication Publication Date Title
KR102466192B1 (ko) 간세포성 암종의 치료를 위한 조합 요법
KR102517650B1 (ko) 유방암의 치료를 위한 조합물 요법
JP7665700B2 (ja) 肝細胞癌の治療のための併用療法
JP2022160654A (ja) 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
JP7704690B2 (ja) 抗癌化合物ｅ７７６６の治療コンプライアンスを向上させるシステム
RU2787993C2 (ru) Комбинированные терапии для лечения гепатоцеллюлярной карциномы

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190322

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200821

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220706

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220908

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221108

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221109

End annual number: 3

Start annual number: 1

PG1601 Publication of registration